I-BET-762: Selective BET Inhibitor for Inflammation and Cancer Research

Executive Summary: I-BET-762 is a potent, selective inhibitor of the BET protein family, binding the acetyl-lysine binding pocket with nanomolar affinity (IC50 32.5–42.5 nM, Kd 50.5–61.3 nM) and displaying high specificity over non-BET bromodomains (ApexBio). It competitively displaces acetyl-lysine residues, downregulating LPS-inducible gene transcription and cytokine production in vitro and in vivo (Fan et al., 2024). I-BET-762 enhances erastin-induced ferroptosis in multiple cancer cell lines by promoting ROS accumulation and reducing FSP1 expression, supporting its role in combinatorial cancer therapy (Fan et al., 2024). The compound is chemically stable as a solid, with high solubility in DMSO and ethanol but is unstable in aqueous solutions. It is widely used in studies of epigenetic regulation, inflammation, and cancer biology, where precise modulation of BET signaling is essential (ApexBio).

Biological Rationale

Bromodomain and extra-terminal domain (BET) proteins, including BRD2, BRD3, BRD4, and BRDT, are epigenetic readers that regulate gene expression by binding acetylated lysine residues on histone tails (Fan et al., 2024). Dysregulation of BET proteins is implicated in inflammation, oncogenesis, and resistance mechanisms in cancer therapy. Inhibiting BET proteins disrupts transcriptional programs driving pro-inflammatory cytokine production and tumor cell survival. I-BET-762, a selective small-molecule BET inhibitor, has emerged as a valuable tool for dissecting these pathways in preclinical models (ApexBio).

Mechanism of Action of I-BET-762

I-BET-762 acts by competitively binding to the acetyl-lysine recognition pocket of BET bromodomains, thereby displacing acetylated histone tails (ApexBio). The compound exhibits a 2:1 binding stoichiometry with BET proteins, contributing to its high affinity (Kd 50.5–61.3 nM) and selectivity. This binding prevents BET-mediated recruitment of transcriptional machinery, resulting in global downregulation of LPS-inducible genes and suppression of pro-inflammatory cytokines and chemokines. In cancer cells, inhibition of BRD4 by I-BET-762 also leads to increased reactive oxygen species (ROS) and downregulation of ferroptosis suppressor protein 1 (FSP1), sensitizing cells to ferroptosis inducers such as erastin (Fan et al., 2024).

Evidence & Benchmarks

• I-BET-762 binds BET bromodomains with an IC50 of 32.5–42.5 nM and a Kd of 50.5–61.3 nM, showing no significant activity against non-BET bromodomains (ApexBio).
• In vitro, 1–2 μM I-BET-762 enhances erastin-induced ferroptosis in HEK293T, HeLa, HepG2, RKO, and PC3 cell lines by increasing ROS and reducing FSP1 expression (Fan et al., 2024).
• ChIP-seq data demonstrate that BRD4 directly binds to the FSP1 promoter; I-BET-762 treatment reduces this binding, leading to decreased FSP1 mRNA and protein levels (Fan et al., 2024).
• In vivo, I-BET-762 ameliorates symptoms in mouse models of inflammatory disease by suppressing LPS-inducible cytokine production (ApexBio).
• I-BET-762 is highly soluble in DMSO (≥21.19 mg/mL) and ethanol (≥13.93 mg/mL with ultrasonication), but is insoluble in water; solutions should be used promptly to avoid degradation (ApexBio).

This article clarifies the molecular benchmarks and mechanistic evidence for I-BET-762 beyond the strategic overview in "I-BET-762: Selective BET Inhibitor for Inflammation and Cancer", detailing condition-specific effects and quantifiable endpoints.

Applications, Limits & Misconceptions

I-BET-762 is primarily used in research targeting epigenetic regulation, inflammation, and cancer biology. Its selectivity for BET proteins makes it ideal for dissecting BET-driven transcriptional programs and validating BET as a therapeutic target. In combination with ferroptosis inducers, I-BET-762 can enhance programmed cell death in certain cancer models. Its utility is supported by robust in vitro and in vivo data.

Common Pitfalls or Misconceptions

• I-BET-762 is not a pan-bromodomain inhibitor: It shows high selectivity for BET family bromodomains and minimal activity against non-BET bromodomains (ApexBio).
• Not suitable for direct clinical use: I-BET-762 is intended for research applications; clinical safety and efficacy are not established (ApexBio).
• Instability in aqueous solution: The compound is insoluble in water and degrades in solution; solutions should be freshly prepared and used immediately (ApexBio).
• BET inhibition alone may not induce ferroptosis: Synergistic effects are observed with ferroptosis inducers such as erastin, not with I-BET-762 monotherapy (Fan et al., 2024).
• Gene expression changes are cell-type specific: The transcriptional response to I-BET-762 may vary depending on the cellular context (Fan et al., 2024).

This article updates the mechanistic landscape beyond "I-BET-762: Precision BET Bromodomain Inhibition as a Translational Tool" by providing detailed evidence for ferroptosis synergy and clarifying compound-specific solubility and storage constraints.

Workflow Integration & Parameters

Preparation and Storage: I-BET-762 is supplied as a solid. Reconstitute in DMSO at ≥21.19 mg/mL or ethanol at ≥13.93 mg/mL (with ultrasonication). Do not attempt to dissolve in water. Store at -20°C. Prepare aliquots to avoid repeated freeze-thaw cycles; use solutions promptly due to instability (ApexBio).

Experimental Use: Typical in vitro concentrations range from 0.5 μM to 2 μM for BET target engagement. For combination studies, co-treat with ferroptosis inducers such as erastin (20 μM, 24–48 h) to assess synergistic effects on ROS and cell viability (Fan et al., 2024).

Readouts: Assess BRD4 target gene expression by qPCR, FSP1/GPX4/VDAC2 protein levels by Western blot, and ROS accumulation via fluorescent probes. For cell death, use propidium iodide staining or CCK-8 cell viability assays. For in vivo models, dose and administration schedule should be optimized based on disease context and pharmacokinetics.

This article extends the mechanistic applications discussed in "I-BET-762: Unraveling BET Inhibition for Ferroptosis and Epigenetic Regulation" by providing concrete workflow parameters and integration guidance for reproducible results.

Conclusion & Outlook

I-BET-762 is a validated, selective BET inhibitor that enables precise modulation of epigenetic regulation and inflammatory signaling in preclinical research. Its synergy with ferroptosis inducers and robust selectivity profile make it a platform compound for dissecting BET-mediated transcriptional programs in cancer biology. For verified product information and workflow resources, see the I-BET-762 product page. Future research should focus on cell-type specific responses, combination strategies, and translational potential in disease models.